The Gut-Brain Axis: How Your Microbiome Affects Your Mood

By Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho

The idea that gut health affects mental health was once considered fringe. Today it is one of the most active areas of neuroscience and psychiatry research, supported by a rapidly growing body of evidence from human clinical trials, animal studies, and epidemiological data.

The gut-brain axis — the bidirectional communication network between the gastrointestinal tract and the central nervous system — is now understood to be a major regulator of mood, cognition, stress response, and neuroplasticity. And the gut microbiome — the 38 trillion microorganisms that inhabit the human gut — is a central player in this system.

The gut and brain communicate through multiple pathways:

The vagus nerve: The primary neural highway between gut and brain, carrying signals in both directions. Approximately 80–90% of vagal fibers are afferent (gut-to-brain), meaning the gut sends far more information to the brain than the brain sends to the gut.

The enteric nervous system: The gut contains approximately 500 million neurons — more than the spinal cord — organized into a complex neural network that operates semi-independently. This "second brain" produces and responds to the same neurotransmitters as the central nervous system.

The immune system: The gut houses approximately 70% of the body's immune cells. Gut microbiome composition directly regulates immune function and systemic inflammation — which, as discussed in our inflammation-depression article, is a major driver of depressive illness.

The HPA axis: Gut microbiota regulate the hypothalamic-pituitary-adrenal axis, influencing cortisol production and stress reactivity.

Neurotransmitter production: The gut produces approximately 90% of the body's serotonin and significant quantities of GABA, dopamine precursors, and other neuroactive compounds.

Multiple studies have identified distinct differences in gut microbiome composition between depressed and non-depressed individuals:

• Depressed patients show reduced diversity of gut microbiota — a consistent marker of poor gut health
• Specific bacterial genera are depleted in depression, including Lactobacillus, Bifidobacterium, and Faecalibacterium prausnitzii (a major butyrate producer with anti-inflammatory properties)
• Pro-inflammatory bacterial species are enriched in depressed patients
• The severity of microbiome disruption correlates with depression severity

Key Reference: Valles-Colomer M, et al. (2019). The neuroactive potential of the human gut microbiota in quality of life and depression. Nature Microbiology, 4(4), 623–632.

Some of the most compelling evidence for the gut-brain connection comes from fecal microbiota transplant (FMT) studies in animals. When gut microbiota from depressed humans are transplanted into germ-free rodents, the animals develop depressive and anxious behaviors — demonstrating that the microbiome itself can transmit a depressive phenotype.

Multiple randomized controlled trials have demonstrated that probiotic supplementation produces measurable improvements in depression and anxiety scores in both healthy volunteers and patients with clinical depression. A 2019 meta-analysis of 34 controlled trials found significant antidepressant and anxiolytic effects of probiotic supplementation.

Key Reference: Huang R, et al. (2016). Effect of probiotics on depression: a systematic review and meta-analysis of randomized controlled trials. Nutrients, 8(8), 483.

A disrupted microbiome compromises the integrity of the intestinal epithelial barrier — a condition commonly called "leaky gut" (intestinal hyperpermeability). When the gut barrier is compromised, bacterial products — particularly lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls — enter the bloodstream.

LPS is a potent activator of the innate immune system, triggering the release of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) that drive the inflammatory depression cascade described in our inflammation-depression article.

Beneficial gut bacteria — particularly Faecalibacterium prausnitzii, Roseburia, and Akkermansia muciniphila — produce short-chain fatty acids (SCFAs) including butyrate, propionate, and acetate through fermentation of dietary fiber.

SCFAs have profound effects on brain health:

• Butyrate is the primary energy source for colonocytes and maintains gut barrier integrity
• SCFAs cross the blood-brain barrier and directly influence microglial function and neuroinflammation
• Butyrate inhibits histone deacetylases (HDACs), producing epigenetic effects that promote BDNF expression and neuroplasticity
• SCFA depletion is associated with increased intestinal permeability, systemic inflammation, and depression

Gut microbiota regulate the production of enterochromaffin cells — the specialized gut cells that produce 90% of the body's serotonin. Dysbiosis disrupts serotonin synthesis and availability, affecting both gut motility and, through vagal signaling, central serotonergic tone.

As with inflammatory depression, dysbiosis activates the kynurenine pathway, shunting tryptophan away from serotonin production toward neurotoxic metabolites.

Understanding the drivers of dysbiosis is essential for treatment:

Antibiotics: The most potent disruptor of gut microbiome diversity. A single course of broad-spectrum antibiotics can reduce microbiome diversity by 25–50%, with recovery taking months to years. Repeated antibiotic courses produce cumulative damage.

Ultra-processed foods: Diets high in refined carbohydrates, industrial seed oils, emulsifiers, and artificial sweeteners dramatically alter microbiome composition, reducing beneficial species and promoting pro-inflammatory bacteria.

Chronic stress: Psychological stress alters gut motility, intestinal permeability, and microbiome composition through HPA axis and autonomic nervous system effects.

Proton pump inhibitors (PPIs): Widely prescribed for acid reflux, PPIs alter gut pH and significantly disrupt microbiome composition with long-term use.

Alcohol: Chronic alcohol consumption is a major driver of dysbiosis and intestinal hyperpermeability.

Sedentary lifestyle: Physical activity promotes microbiome diversity; sedentary behavior is associated with reduced diversity.

Increase dietary fiber: Fiber is the primary substrate for beneficial gut bacteria. The Mediterranean diet, rich in vegetables, legumes, whole grains, and fruits, consistently improves microbiome diversity and reduces depression scores.

Fermented foods: Yogurt, kefir, sauerkraut, kimchi, and other fermented foods introduce beneficial bacteria and their metabolites. A 2021 Stanford randomized trial demonstrated that a high-fermented-food diet significantly increased microbiome diversity and reduced inflammatory markers.

Reduce ultra-processed foods: Eliminating or dramatically reducing ultra-processed foods is one of the most impactful dietary changes for gut health.

Polyphenol-rich foods: Berries, dark chocolate, olive oil, and green tea contain polyphenols that selectively feed beneficial bacteria.

The evidence for probiotics in depression is strongest for multi-strain formulations containing Lactobacillus and Bifidobacterium species. The concept of psychobiotics — probiotics specifically selected for their mental health effects — is an active area of research.

Clinically useful strains include:

• Lactobacillus rhamnosus (JB-1) — reduces anxiety and cortisol in animal models
• Bifidobacterium longum (1714) — reduces stress and improves memory in human trials
• Lactobacillus helveticus + Bifidobacterium longum combination — reduces anxiety and depression in clinical trials

Prebiotics — non-digestible fibers that selectively feed beneficial bacteria — include inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS). Prebiotic supplementation has demonstrated anxiolytic effects and improvements in stress reactivity in human trials.

Effective gut health restoration requires identifying and addressing the drivers of dysbiosis: minimizing unnecessary antibiotic use, treating underlying conditions driving PPI use, reducing alcohol consumption, and managing chronic stress.

For patients with treatment-resistant depression, gut health assessment is a valuable component of the functional medicine evaluation. Patients with:

• History of frequent antibiotic use
• Irritable bowel syndrome or inflammatory bowel disease
• Significant dietary history of ultra-processed food consumption
• Prominent fatigue, brain fog, and somatic symptoms alongside depression
• Elevated inflammatory markers

...may have a significant gut-brain axis contribution to their depression that conventional antidepressants cannot address.

At Roth Family Medicine, we integrate gut health assessment into our functional medicine approach to treatment-resistant depression, alongside evaluation of inflammatory markers, hormonal status, nutritional deficiencies, and sleep disorders.

How long does it take to improve gut health? Microbiome changes can be detected within days of dietary changes, but meaningful restoration of diversity typically takes weeks to months. Consistency is key — the microbiome responds to sustained dietary patterns, not short-term interventions.

Should I get a gut microbiome test? Commercial microbiome tests are available but have significant limitations in clinical interpretation. We currently recommend focusing on evidence-based dietary and lifestyle interventions rather than expensive microbiome testing for most patients.

Can improving gut health replace antidepressants? For most patients, gut health optimization is a complementary intervention, not a replacement for conventional treatment. However, for patients with significant dysbiosis-driven depression, addressing gut health can produce meaningful improvements that antidepressants alone cannot achieve.

1. Valles-Colomer M, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623–632.
2. Huang R, et al. Effect of probiotics on depression: a systematic review and meta-analysis. Nutrients. 2016;8(8):483.
3. Sonnenburg JL, Sonnenburg ED. Vulnerability of the industrialized microbiota. Science. 2019;366(6464):eaaw9255.
4. Cryan JF, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877–2013.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice.

Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho | 208-904-4705 | www.rothfamilymed.com